🌟 Just 1 Week to Go Until #APCCC24 ! 🌟

🚀 Are you ready for the most anticipated oncology conference of the year? APCCC 2024 kicks off next week, April 25-27, in the stunning city of Lugano🇨🇭!

With our hybrid format, don't miss your chance to be part of this transformative

With less than a week until #APCCC24 begins, we’re highlighting again the crucial sessions on systemic therapy side effects and metastatic CRPC management.

Whether you join us in the city of Lugano🇨🇭or tune in virtually, these discussions are pivotal for anyone interested in

Join me @ #RADAIM24 July 27-28 Gold Coast

CT | MIR | AI | PET

Register now: radaim.com

The #MelPedal24 is well underway and we're cheering from the sidelines!

Thank you to all our #MelPedal24 riders and supporters for your amazing efforts - we couldn't do it without you! Donate here to help us reach our fundraising target belowthebelt.org.au/event/melbourn…

Congratulations to our dear friend Rana for receiving the prestigious 2024 Christopher G. Wood Rising Star Award at the IKCS Europe, a well-earned recognition of her exceptional work in kidney cancer research! Your dedication and hard work have truly paid off. Cheers to your

Discover this research by Mark S Stein et al. demonstrating in vivo glucagon-like peptide-1 receptor (GLP-1R) expression by human metastatic castrate-resistant #prostate #cancer 👉 ow.ly/eO8850Rj7RX Michael Hofman

Piet Ost Alberto Bossi To my mind, the case for prostate RT in high-burden disease rests on prevention of complications of local progression, for which Craig Jones presented evidence from STAMPEDE at ESMO 2023

Three leading drugmakers have spent about $8 billion in the past six months to purchase companies developing radiopharmaceuticals to fight cancer bloomberg.com/news/articles/…

Mr. @Moad Esa will talk about the power of Auger Electrons in treatment of cancer and will provide an overview about the preclinical studies and clinical Phase I/II of Tb161-PSMA-I&T which we are supporting at the @Peter Mac Cancer Center in Australia.

Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy jnm.snmjournals.org/content/early/…

Ahead of hitting the road, Ambassador Kennedy spoke with media about why she was inspired to join Box Rallies and how hopeful she is after meeting cancer researchers at Peter Mac Cancer Centre, Garvan Institute of Medical Research, Melanoma Institute Australia, and WEHI (Walter and Eliza Hall Institute).

Bravo Ambassador Kennedy 👏 Thank you for supporting cancer research in Australia. Enjoy our beautiful outback….. I’m sure it will be a blast! Box Rallies Peter Mac Cancer Centre Garvan Institute of Medical Research WEHI (Walter and Eliza Hall Institute) Melanoma Institute Australia Tara Brown

ENZA-P in The Lancet Oncology

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from Louise Emmett Ian Davis & ANZUP team

ENZA-P in The Lancet Oncology

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from Louise Emmett Ian Davis & ANZUP team

Is Terbium-161 (¹⁶¹Tb) Really Happening ??

jnm.snmjournals.org/content/jnumed… JNM

#GraceKong James Buteau ProsTIC

Prostate cancer cases are projected to double to 2.9 million per year by 2040.

🆕 A Lancet Commission outlines evidence-based interventions, such as improved early detection & education programmes, to help save lives & prevent related ill health. hubs.li/Q02snzFs0

#ProsTIC24 ProsTIC #Melbourne highlights

youtu.be/DutkLI0GAUQ

Interviews with Ken Herrmann Howard Soule participants from Philippines, China, Spain & Mexico

Thanks Declan Murphy for capturing the atmosphere
on this outstanding #GUcast episode... don't forget to

One in 8 men in the U.S. will develop prostate cancer (PCa) in their lifetime, and the disease can progress to metastatic castration-resistant PCa, with limited treatments and poor overall survival.​ bit.ly/3vsMmhT